ACTIVITY OF THE PAN-HER TYROSINE KINASE (TK) INHIBITOR DACOMITINIB (PF-00299804) IN REFRACTORY NONADENOCARCINOMA (NON-A) NON-SMALL CELL LUNG CANCER (NSCLC) AND COMPARED WITH ERLOTINIBIN THE 2ND-/3RD-LINE SETTING

Documents similaires

• Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
  par: Ramalingam, S, et autres
  Publié: (2012)
• Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
  par: Justin P Williams, et autres
  Publié: (2014-01-01)
• Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
  par: Jinyao Zhang, et autres
  Publié: (2021-12-01)
• Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
  par: Lavacchi D, et autres
  Publié: (2019-09-01)
• Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
  par: Xingxiang Pu, et autres
  Publié: (2023-10-01)